Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UCB-Treg and Liraglutide in Autoimmune Diabetes
NCT03011021Phase 2Unknown
- Sponsor
- The Second Xiangya Hospital
- Start
- Jan 2017
- Primary completion
- Jun 2025
- Modality
- Peptides, Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of umbilical cord blood regulatory T cells and liraglutide in type 1 diabetes mellitus (T1D) and latent autoimmune diabetes in adults (LADA) (4 arms), sponsored by The Second Xiangya Hospital. Primary endpoint: Adverse effects at 2 years. Status: unknown.
02
Drugs
umbilical cord blood regulatory T cellsliraglutide
03
Conditions
type 1 diabetes mellitus (T1D)latent autoimmune diabetes in adults (LADA)
Beyond the preview
Go deeper on NCT03011021.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03011021.